

Are you leading an up-and-coming life sciences and biotech start-up venture?

At Novo Nordisk we are committed to discovering, creating, and co-creating innovation to solve healthcare challenges for people living with diabetes, obesity, cardiovascular disease, NASH, chronic kidney disease, and blood and endocrine disorders. One way of doing this is by lowering the entry barriers to biotech for life science entrepreneurs and fuel the next generation of innovators and life-saving technologies.

Science2Medicine creationNN is a collaboration with BioLabs, the premiere life science incubator whose mission is to foster innovation and entrepreneurship, and its Golden Ticket program. Through this award, we will support 2 rent-free lab spaces* at BioLabs Heidelberg and 2 at BioLabs Paris. You will get access to a dedicated lab bench and shared facilities allowing you to concentrate on your innovative science, while BioLabs take care of the lab management. In collaboration with our partner BioLabs, Science2Medicine creationNN aims to offer the entrepreneurial base for your laboratory work.

Are you interested to reside among the biotech and medtech superstars, working on developing breakthrough innovations? Send us your application and unique value proposition that addresses a significant unmet need for patients with cardio-metabolic diseases , rare haematology or endocrine disorders **by 12pm Central European Time on 23 October 2022.**

* Each Golden Ticket provides 1 bench, 1 desk, and 1 membership for 1 year.

WHY PARTICIPATE

- ✓ **1-year all-inclusive, rent-free lab space** to de-risk your technology and scale your business
- ✓ **No strings attached** since IPR belongs to you
- ✓ **Network connections** with other organisations and investors through the local innovation eco-system
- ✓ **Mentoring and support** from our experts
- ✓ **Located at BioLabs Heidelberg & Paris**, our partner and the hottest start-up incubators in Europe.

Good to know before you apply

To get your application evaluated, go to our website, describe your proposal in detail and answer the questions. We recommend that you attach a pitch deck and/or video.

The applications are assessed by a scientific expert panel. Their assessments are based on four evaluation criteria;

- ✓ Scientific novelty
- ✓ Scalability and impact
- ✓ Robustness of the research plan
- ✓ Team competency

[SUBMIT YOUR APPLICATION](#)

If you are seeking inspiration, here is list of example research topics that are of particular interest to us, although we welcome anything beyond this list that is within the remit of our disease and technology areas:

Therapy areas		Examples:
THERAPEUTICS & DRUG TARGETS	DIABETES	<ul style="list-style-type: none"> ❑ Efficacy beyond BG lowering, e.g. co-morbidity risk reduction ❑ Reversal of insulin resistance ❑ Prevention of disease progression, e.g. preservation of beta-cell health (T1D/T2D)
	OBESITY	<ul style="list-style-type: none"> ❑ Enhancement of energy expenditure ❑ Modulation of eating behaviour (eg. hedonic and reward signalling) ❑ Modulation of the counter-regulatory mechanisms (e.g. metabolic set-point)
	CARDIOVASCULAR DISEASE	<ul style="list-style-type: none"> ❑ 'Atherosclerotic CVD, HFpEF & cardiomyopathies ❑ MoAs providing risk reduction additive to LDL/TG lowering and anti-inflammation ❑ Precision-medicine approaches to heart failure ❑ Disease-modification (eg. gene therapy)
	KIDNEY DISEASE	<ul style="list-style-type: none"> ❑ CKD/DKD, polycystic kidney disease & glomerulonephritis ❑ Fibrosis resolution/inhibition of fibrogenesis ❑ Preservation of vascular and glomerular integrity
	LIVER DISEASE (NASH)	<ul style="list-style-type: none"> ❑ Fibrosis resolution/inhibition of fibrogenesis ❑ Suppression of chronic inflammation ❑ Liver regenerative approaches ❑ Non-invasive diagnostic biomarkers
TECHNOLOGY	RARE DISEASES	<ul style="list-style-type: none"> ❑ Rare, non-malignant hematologic diseases ❑ Rare endocrine diseases
	DRUG DISCOVERY	<ul style="list-style-type: none"> ❑ Oral delivery of biologic drugs ❑ Tissue-selective delivery of nucleic acid medicines ❑ Non-viral gene delivery methods
	DRUG MODALITIES	<ul style="list-style-type: none"> ❑ Stem cell-based therapies ❑ Genome editing technology